Search Results - "Brock, William J."

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors by Woodhead, Jeffrey L, Brock, William J, Roth, Sharin E, Shoaf, Susan E, Brouwer, Kim L R, Church, Rachel, Grammatopoulos, Tom N, Stiles, Linsey, Siler, Scott Q, Howell, Brett A, Mosedale, Merrie, Watkins, Paul B, Shoda, Lisl K M

“…Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic…”
Get full text

Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease by Bezençon, Jacqueline, Beaudoin, James J, Ito, Katsuaki, Fu, Dong, Roth, Sharin E, Brock, William J, Brouwer, Kim L R

“…Autosomal dominant polycystic kidney disease (ADPKD) is a common form of inherited polycystic kidney disease (PKD) and is a leading cause of kidney failure…”
Get full text

Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury? by Slizgi, Jason R, Lu, Yang, Brouwer, Kenneth R, St Claire, Robert L, Freeman, Kimberly M, Pan, Maxwell, Brock, William J, Brouwer, Kim L R

“…Tolvaptan is a vasopressin V(2)-receptor antagonist that has shown promise in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was,…”
Get full text

Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease by Brock, William J., Beaudoin, James J., Slizgi, Jason R., Su, Mingming, Jia, Wei, Roth, Sharin E., Brouwer, Kim L. R.

“…Polycystic kidney disease is characterized by the progressive development of kidney cysts and declining renal function with frequent development of cysts in…”
Get full text

Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment by Bassan, Arianna, Steigerwalt, Ronald, Keller, Douglas, Beilke, Lisa, Bradley, Paul M, Bringezu, Frank, Brock, William J, Burns-Naas, Leigh Ann, Chambers, Jon, Cross, Kevin, Dorato, Michael, Elespuru, Rosalie, Fuhrer, Douglas, Hall, Frances, Hartke, Jim, Jahnke, Gloria D, Kluxen, Felix M, McDuffie, Eric, Schmidt, Friedemann, Valentin, Jean-Pierre, Woolley, David, Zane, Doris, Myatt, Glenn J

“…The ICH S1B carcinogenicity global testing guideline has been recently revised with a novel addendum that describes a comprehensive integrated Weight of…”
Get full text

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats by Tillman, Erik J., Brock, William J., Rolph, Tim

“…Background and Purpose Analogues of fibroblast growth factor 21 (FGF21) demonstrate diverse metabolic benefits in preclinical models of type 2 diabetes,…”
Get full text

A weight of evidence evaluation of the mode of action of isoeugenol by Brock, William J., Greene, Tracy, Van Landingham, Cynthia, Gentry, Robinan

“…Isoeugenol is one of several phenylpropenoid compounds that is used as a fragrance, food flavoring agent and in aquaculture as a fish anesthetic…”
Get full text

Introduction to the WEEL values of selected fluorocarbons by Brock, William J

Get full text

Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity by Beaudoin, James J., Brock, William J., Watkins, Paul B., Brouwer, Kim L. R.

“…Patients with autosomal dominant polycystic kidney disease (ADPKD) exhibit enhanced susceptibility to tolvaptan hepatotoxicity relative to other patient…”
Get full text

miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model by Mosedale, Merrie, Eaddy, J Scott, Trask, O Joseph, Holman, Natalie S, Wolf, Kristina K, LeCluyse, Edward, Ware, Brenton R, Khetani, Salman R, Lu, Jingtao, Brock, William J, Roth, Sharin E, Watkins, Paul B

“…Abstract Idiosyncratic drug-induced liver injury (IDILI) is thought to often result from an adaptive immune attack on the liver. However, it has been proposed…”
Get full text

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease by Beaudoin, James J, Bezençon, Jacqueline, Cao, Yanguang, Mizuno, Katsuhiko, Roth, Sharin E, Brock, William J, Brouwer, Kim L R

“…Tolvaptan, a vasopressin V -receptor antagonist, has demonstrated efficacy in slowing kidney function decline in patients with autosomal dominant polycystic…”
Get full text

Current Trends of Practices in Nonclinical Toxicology: An Industry Survey by Authier, Simon, Brock, William J, Halpern, Wendy, Harris, Stephanie N, Jones, David, McGovern, Timothy, McGovern, Pamela D, Pugsley, Michael K

“…The growth in drug development over the past years reflects significant advancements in basic sciences and a greater understanding of molecular pathways of…”
Get full text

Strengthening the Peer Review Process for the International Journal of Toxicology by Brock, William J.

Get full text

Scientific conduct... and misconduct by Genter, Mary Beth, Brock, William J, Mattes, William B

Get full text

Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease by Shimomura, Yuichi, Brock, William J., Ito, Yuko, Morishita, Katsumi

“…PCK rats develop age-related polycystic kidney disease (PKD) and liver disease and have been used to investigate pharmacotherapies to ameliorate hepatorenal…”
Get full text

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes by Lu, Yang, Slizgi, Jason R, Brouwer, Kenneth R, Claire, Robert L St, Freeman, Kimberly M, Pan, Maxwell, Brock, William J, Brouwer, Kim L

“…Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP3A. The present study investigated the hepatocellular disposition of tolvaptan and…”
Get full text

Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach by Mosedale, Merrie, Kim, Yunjung, Brock, William J, Roth, Sharin E, Wiltshire, Tim, Eaddy, J Scott, Keele, Gregory R, Corty, Robert W, Xie, Yuying, Valdar, William, Watkins, Paul B

“…Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed…”
Get full text

The In Vitro and In Vivo Genotoxicity of Benzocaine: A Brief Communication by Brock, William J., Bell, Thomas A.

“…Benzocaine has a long history of use in human medicine. However, benzocaine also has been used in aquaculture with finfish for more than 40 years for sedating…”
Get full text

Ocular Toxicity Assessment From Systemically Administered Xenobiotics: Considerations in Drug Development by Brock, William J., Somps, Christopher J., Torti, Vince, Render, James A., Jamison, Jeffrey, Rivera, Maria I.

“…The eye is a unique sensory structure, which must be evaluated for toxicity to determine the safety of drugs, industrial chemicals, and consumer products…”
Get full text

Oral Repeat Dose and Reproductive Toxicity of the Chlorinated Flame Retardant Dechlorane Plus by Brock, William J., Schroeder, Raymond E., McKnight, Christy A., VanSteenhouse, Jan L., Nyberg, Janice M.

“…This study consisted of a 28-day oral repeat dose (repeat dose toxicity [RDT]) phase and a developmental and reproductive (developmental and reproductive…”
Get full text